Sarfez Pharmaceuticals, Inc.
🇺🇸United States
Clinical Trials
12
Active:0
Completed:3
Trial Phases
5 Phases
Phase 1:3
Phase 2:4
Phase 3:1
+2 more phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (33.3%)Phase 1
3 (25.0%)Not Applicable
2 (16.7%)Phase 4
2 (16.7%)Phase 3
1 (8.3%)Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
Not Applicable
Recruiting
- Conditions
- Bioavailability Heathy Volunteers
- Interventions
- Drug: Torsemide and Spironolactone tabletDrug: Torsemide Tablets and Spironolactone Tablets
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07046975
- Locations
- 🇺🇸
Sarfez Pharmaceuticals, Vienna, Virginia, United States
A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
Not Applicable
Recruiting
- Conditions
- Bioavailability Heathy Volunteers
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07043634
- Locations
- 🇺🇸
Sarfez Pharmaceuticals, Vienna, Virginia, United States
Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects
Phase 3
Recruiting
- Conditions
- Bioequivalence Study in Healthy SubjectsPK/PD
- Interventions
- Drug: 10 mg Torsemide tabletDrug: 25 mg Aldactone (Spironolactone) tabletDrug: FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07015671
- Locations
- 🇺🇸
Sarfez Pharmaceuticals, Vienna, Virginia, United States
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
Phase 4
Recruiting
- Conditions
- Heart FailureEdemaPulmonary CongestionFluid Overload
- Interventions
- Drug: Extended Release Torsemide TabletsDrug: Immedate Release Torsemide Tablets
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06995144
- Locations
- 🇺🇸
Future Life Clinical Trials, Miami, Florida, United States
A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06708611
- Locations
- 🇺🇸
Future Life Clinical Trials, Miami, Florida, United States
- Prev
- 1
- 2
- Next
News
No news found